Masato Yanagi

ORCID: 0000-0003-0203-1954
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Childhood Cancer Survivors' Quality of Life
  • Neutropenia and Cancer Infections
  • Hematopoietic Stem Cell Transplantation
  • Renal and related cancers
  • Acute Lymphoblastic Leukemia research
  • Renal cell carcinoma treatment
  • Blood disorders and treatments
  • Prostate Cancer Diagnosis and Treatment
  • Bladder and Urothelial Cancer Treatments
  • Urinary and Genital Oncology Studies
  • Acute Myeloid Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Prostate Cancer Treatment and Research
  • Chronic Myeloid Leukemia Treatments
  • Colorectal Cancer Treatments and Studies
  • Neuroblastoma Research and Treatments
  • Cancer Immunotherapy and Biomarkers
  • Lymphoma Diagnosis and Treatment
  • AI in cancer detection
  • Radiomics and Machine Learning in Medical Imaging
  • Metastasis and carcinoma case studies
  • Urological Disorders and Treatments
  • Chemotherapy-induced organ toxicity mitigation
  • Glioma Diagnosis and Treatment
  • Antifungal resistance and susceptibility

Nippon Medical School
2022-2024

Sapporo Hokuyu Hospital
2020-2024

Saitama Children's Medical Center
2017-2024

Nippon Medical School Hospital
2019-2024

Palmetto Hematology Oncology
2017-2022

Maryland Oncology Hematology
2022

Suzuki (Japan)
2020

National Hospital Organization Saitama Hospital
2020

National Hospital Organization
2020

Okayama University
2011

This study presents the enfortumab vedotin (EV) treatment analysis at our institution. We retrospectively analyzed patients with metastatic urothelial cancer (mUC) treated EV between January 2021 and October 2023. was administered 1.25 mg/kg on days 1, 8, 15 in a 28-day cycle. Whole-body computed tomography scans were performed to assess response. Patient characteristics, histories, response rates, progression-free survival, adverse events evaluated. Response rates determined, recorded....

10.3390/curroncol31020056 article EN cc-by Current Oncology 2024-01-29

Deep learning algorithms have achieved great success in cancer image classification. However, it is imperative to understand the differences between deep and human approaches. Using an explainable model, we aimed compare learning-focused regions of magnetic resonance (MR) images with cancerous locations identified by radiologists pathologists. First, 307 prostate MR were classified using a well-established neural network without locational information cancers. Subsequently, assessed whether...

10.3390/biom9110673 article EN cc-by Biomolecules 2019-10-30

Abstract Accurate prostate cancer screening is imperative for reducing the risk of death. Ultrasound imaging, although easy, tends to have low resolution and high inter-observer variability. Here, we show that our integrated machine learning approach enabled detection pathological high-grade by ultrasound procedure. Our study included 772 consecutive patients 2899 images obtained at Nippon Medical School Hospital. We applied analyses using imaging data clinical detect cancer. The area under...

10.1038/s41598-022-04951-3 article EN cc-by Scientific Reports 2022-01-17

Abstract A male patient diagnosed with severe congenital protein C (PC) deficiency during the neonatal period was treated long‐term warfarin but frequently developed purpura fulminans and bleeding. At four years of age, edoxaban initiated (direct oral anticoagulant [DOAC]). His d ‐dimer fibrin/fibrinogen degradation product levels were closely monitored. PC activity increased from below sensitivity range to 17%; this increase thought be due a reduction in consumption therapy. After...

10.1002/pbc.27686 article EN Pediatric Blood & Cancer 2019-03-05

Abstract Background Urolithiasis is an extremely rare complication in childhood acute lymphoblastic leukemia (ALL), and some reports have implicated corticosteroids during chemotherapy as a risk factor for it. However, only few analyzed urinary electrolytes this context. Methods We retrospectively 55 patients with ALL who underwent between October 2007 January 2019. Their median age was 9.3 years (range, 0.3–24.0 years) 30 males 25 females. Lineages were B‐cell precursor (BCP‐ALL) 42...

10.1111/ped.14527 article EN Pediatrics International 2020-10-31

Background: Long-term venous access is essential when treating malignant diseases. As an alternative to conventional central catheters, peripherally inserted catheter (PICC) are now widely used. The aim of this study evaluate the safety, efficacy, and reliability PICCs in comparison with previous reports, describe significant complications associated their use. Patients Methods: From June 2009 November 2017, were 258 times a total 160 pediatric young adult patients at our institution. We...

10.1097/mph.0000000000001719 article EN Journal of Pediatric Hematology/Oncology 2020-02-25

Active surveillance (AS) is one of the treatment methods for patients with small renal masses (SRMs; < 4 cm), including cell carcinomas (RCCs). However, some RCCs may exhibit aggressive neoplastic behaviors and metastasize. Little known about imaging biomarkers capable identifying potentially RCCs. Contrast-enhanced computed tomography (CECT) often detects collateral vessels arising from angiogenesis in Therefore, this study aimed to evaluate association between SRM differential diagnoses...

10.1186/s12885-022-09971-w article EN cc-by BMC Cancer 2022-08-05

Double-headed trifluorolactate (1) (benzene-1,3-(S,S)-bis(butyl-3,3,3-trifluorolactate), is composed of a bundle tubes held together by two lines infinite hydrogen bonding chains. Two neighboring hydrogen-bonded molecules on the same chain are not connected directly to other chain. That is, tube structure cannot be simple layer stacks.

10.1039/c1ce05663h article EN CrystEngComm 2011-01-01

Adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) are more likely to have chemotherapy-related complications than children. In addition, several reports shown that infections account for most of the therapy-related mortality during cancer treatment in AYAs. Thus, we hypothesized chemotherapy-induced myelosuppression is severe AYAs children, state neutropenia was compared between children using D-index, a numerical value calculated from duration depth...

10.1002/pbc.28763 article EN Pediatric Blood & Cancer 2020-10-13

The authors declare no conflict of interest. Figure S1 S2 S3 Please note: publisher is not responsible for the content or functionality any supporting information supplied by authors. Any queries (other than missing content) should be directed to corresponding author article.

10.1111/ped.15374 article EN Pediatrics International 2022-01-01

Hepatic cirrhosis is a very rare complication of hematopoietic stem cell transplantation (SCT) and neuroblastoma. We encountered two patients developing after SCT against A 6-year-old boy who had received allogeneic bone marrow developed 10 years the with massive upper gastrointestinal hemorrhage. 27-year-old man receiving cord blood recurrence neuroblastoma, died liver failure due to histological 1 year SCT. could not detect definite etiologic candidates cirrhosis; however, careful...

10.22541/au.170669176.64034123/v1 preprint EN Authorea (Authorea) 2024-01-31

<title>Abstract</title> Background The management of chemotherapy-induced nausea and vomiting (CINV) is primary concern for both patients with cancer medical workers. Refractory or breakthrough CINV especially difficult to deal necessitates a different approach. Vitamin B1 deficiency likely occur during chemotherapy, early symptoms fatigue, anorexia, vomiting. efficacy vitamin the treatment delayed refractory should be confirmed. Methods Serum level was prospectively measured in experiencing...

10.21203/rs.3.rs-4250292/v1 preprint EN cc-by Research Square (Research Square) 2024-04-25

Abstract Background Index tumors are the most aggressive of prostate. However, their clinical significance remains unclear. This study aimed to assess incidence index tumor location according zonal origin and whether these locations affect prognosis after radical prostatectomy in patients with negative surgical margins. Methods single-centered, retrospective evaluated 1,109 consecutive who underwent prostatectomies. An was defined as largest prostate gland. We detected based on McNeal's...

10.1186/s12894-024-01499-4 article EN cc-by BMC Urology 2024-05-18

Background. The management of chemotherapy-induced nausea and vomiting (CINV) is primary concern for both patients with cancer medical workers. Refractory or breakthrough CINV especially difficult to deal necessitates a different approach. Vitamin B1 deficiency likely occur during chemotherapy, early symptoms fatigue, anorexia, vomiting. efficacy vitamin the treatment delayed refractory should be confirmed. Methods. Serum level was prospectively measured in experiencing persistent after...

10.22541/au.172490858.80962113/v1 preprint EN Authorea (Authorea) 2024-08-29

45 Background: Does tumor location affect prostate cancer prognosis? To clarify this question we conducted a retrospective study to characterize the incidence and prognostic significance of cancer. Methods: From 2000 2017, radical prostatectomy with no neoadjuvant therapy was performed in 916 cases our hospital. Serial whole mount sections were reviewed determine incidence, clinicopathological features gland. For location, defined subzones, which made from subdivision McNeal’s zonal anatomy,...

10.1200/jco.2019.37.7_suppl.45 article EN Journal of Clinical Oncology 2019-03-01

Gilteritinib is an FMS-like tyrosine kinase 3 (FLT3) inhibitor that has shown efficacy in patients with refractory or recurrent adult acute myeloid leukemia (AML) FLT3 mutations. However, there are limited data for pediatric treated this drug. Herein, we report the clinical courses of two children FLT3-mutated AML who received gilteritinib. Case 1: An 11-year-old boy secondary relapsed presented internal tandem duplication (ITD) since first recurrence. One week after gilteritinib initiation,...

10.11406/rinketsu.61.322 article EN PubMed 2020-01-01
Coming Soon ...